Bayer Healthcare LLC

Wuxi Biologics Ireland Limited

Cstone Pharmaceuticals

Cstone Pharmaceuticals (shanghai) Co., Ltd.

Cstone Pharmaceuticals (suzhou) Co., Ltd.

Wuxi Biologics (shanghai) Co., Ltd.

Wuxi Biologies (shanghai) Co., Ltd.

Cstone Pharmaceutical (suzhou) Co., Ltd.

Cstone Pharmaceuticals Co., Ltd.

Zhuozhi Wang

Jan Tebbe

Jianqing Xu

Haiyan Jiang

Jing Li

Christian Votsmeier

Joerg Birkenfeld

Nina Wobst

Junliang Pan

Susanne Steinig

Peter Scholz

Gennady Gololobov

Bing Liu

Xiao-Yan Zhao

Ji-Yun Kim

Ruth Winter

Ying Zhu

Joanna Grudzinska

Simone Brueckner

Yong Sen Zheng

Dong Sheng Li

Tobias Marquardt

John R Murphy

Joanna Grudzinska-Goebel

Dieter Moosmayer

John E Murphy

Jieying Liu

Qin Mei

Simone Brückner

Dong Li

Xinhua Zhang

Zhewei Tang

Baotian Yang

Jörg Birkenfeld

John Murphy

Yong Zheng

Simone BRÜCKNER

A polypeptide complex comprises antibody variable regions of the heavy chain and light chain respectively fused to TCR constant regions. A bispecific antigen binding polypeptide complex contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety. A method comprises producing the polypeptide complex or the bispecific antigen binding polypeptide complex. A method of treating disease or disorder comprises using the polypeptide complex or the bispecific antigen binding polypeptide complex. A polynucleotide encodes the polypeptide complex and/or the bispecific antigen binding polypeptide complex. A vector or a host cell contains the polynucleotide. A composition and a pharmaceutical composition comprise the polypeptide complex and/or the bispecific antigen binding polypeptide complex.

Bispecific polypeptide complexes

The present invention provides CTLA-4 monoclonal antibodies, particularly humanized monoclonal antibodies specifically binding to CTLA-4 with high affinity. The present invention also provides functional monoclonal antibodies cross-reactive to CTLA-4 of human, cynomolgus monkey and mouse. The present invention further provides amino acid sequences of the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. The epitopes of the antibodies are identified. Therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating cancers and other diseases with anti-CTLA-4 antibodies.

Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)

The present invention provides PD-1 monoclonal antibodies, particularly human monoclonal antibodies of PD-1, which specifically bind to PD-1 with high affinity and comprise a heavy chain and a light chain. The present invention further provides nucleic acid sequence encoding the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. Immunoconjugates, therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating various cancers with anti-PD-1 antibodies.

Monoclonal antibodies to programmed death 1 (PD-1)

A bispecific anti-CD3&#xd7;CD19 polypeptide complex that contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety, methods of producing the bispecific anti-CD3&#xd7;CD19 polypeptide complex, methods of treating disease or disorder using the bispecific anti-CD3&#xd7;CD19 polypeptide complex, polynucleotides encoding the bispecific anti-CD3&#xd7;CD19 polypeptide complex, vectors and host cells containing said polynucleotides, and compositions and pharmaceutical compositions comprising the bispecific anti-CD3&#xd7;CD19 polypeptide complex are provided.

Bispecific CD3/CD19 polypeptide complexes

Provided are humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. Methods of treatment employing these antibodies are described herein.

Humanized monoclonal antibodies against activated protein c and uses thereof

Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.

Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)

This disclosure provides protease-regulated antibodies which specifically bind to tissue factor pathway inhibitor (TFPI). The antibodies are useful for treating bleeding disorders such as hemophilia.

Thrombin/plasmin-regulated antibodies that bind TFPI

Humanized monoclonal antibodies against activated protein C and uses thereof

Antibodies are disclosed that bind to and inhibit the anti-coagulant function of TFPI and have a lower affinity for TFPI at pH 6.0 than at pH 7.4. The lower affinity at pH 6 improves circulating half-life (T&#xbd;) due to reduced target mediated clearance, a process by which an antibody/antigen complex is endocytosed and trafficked to the lysosome where both components are degraded. The lower affinity at pH 6.0 results in disruption of the complex prior to lysosome targeting and allows for re-circulation of the antibody. Specific modifications to antibody binding by histidine residue substitution are disclosed along with methods of use.

Anti-TFPI antibody variants with differential binding across PH range for improved pharmacokinetics

Growing community of inventors

Millbrae, CA, United States of America

Zhuozhi Wang